Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 4/20 | 0.41 |
| ▸ | DRD1 | P21728 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18794436 | 0.89 | UCHL1 (0.41) | UCHL1DRD1DDB1CRBNGHSR | |
| SCHEMBL17681686 | 0.89 | UCHL1 (0.41) | UCHL1DRD1DDB1CRBNGHSR | |
| SCHEMBL30878563 | 0.88 | UCHL1 (0.43) | UCHL1DRD1DDB1CRBNGHSR | |
| SCHEMBL30878494 | 0.87 | UCHL1 (0.40) | UCHL1DRD1TSHRDDB1CRBN | |
| SCHEMBL19512679 | 0.86 | UCHL1 (0.39) | UCHL1DRD1TSHRDDB1CRBN | |
| SCHEMBL30878601 | 0.86 | UCHL1 (0.39) | UCHL1DRD1TSHRDDB1CRBN | |
| SCHEMBL24529009 | 0.85 | UCHL1 (0.39) | UCHL1DRD1DDB1CRBNGHSR | |
| SCHEMBL24528905 | 0.84 | UCHL1 (0.38) | UCHL1DRD1DDB1CRBNGHSR | |
| SCHEMBL17681745 | 0.84 | UCHL1 (0.38) | UCHL1DRD1GHSRALDH1A1CYP3A4 | |
| SCHEMBL22180581 | 0.84 | UCHL1 (0.38) | UCHL1DRD1GHSRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | UCHL1 261/4885DRD1 2057/4885TSHR 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.